Equities research analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to announce earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.45). TG Therapeutics posted earnings per share of ($0.59) in the same quarter last year, which suggests a positive year over year growth rate of 20.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that TG Therapeutics will report full year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($1.91) to ($1.15). For the next year, analysts anticipate that the company will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.71) to ($0.84). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for TG Therapeutics.
TGTX has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. Jefferies Financial Group restated a “buy” rating and issued a $8.00 target price on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley assumed coverage on TG Therapeutics in a report on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price objective on the stock. BidaskClub upgraded TG Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald assumed coverage on TG Therapeutics in a report on Friday, March 29th. They issued an “overweight” rating and a $17.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. TG Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.07.
NASDAQ:TGTX opened at $8.09 on Tuesday. TG Therapeutics has a 52 week low of $3.32 and a 52 week high of $16.00. The firm has a market capitalization of $711.69 million, a price-to-earnings ratio of -4.24 and a beta of 2.31.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.